Results 141 to 150 of about 114,575 (218)
Placebo arms show substantial improvement in cholestatic pruritus, with up to 30% response rate. Estimates differed across outcome instruments, highlighting the importance of endpoint selection and realistic placebo assumptions in future trial design.
Igor Boechat Silveira +8 more
wiley +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Crosstalk between cysteine and lysine modifications: Integrating redox and metabolic regulation. [PDF]
Mitchem EC, Roede JR, Fritz KS.
europepmc +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Design, <i>in Vitro</i> Biological Activities and Molecular Dynamics Simulations of Novel Chalcone and Pyrazole Derivatives Targeting α‑Glucosidase and PPAR‑γ as Antidiabetic Agents. [PDF]
Kurşun Aktar BS +6 more
europepmc +1 more source
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo +4 more
wiley +1 more source
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. [PDF]
Romeo M +10 more
europepmc +1 more source
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli +6 more
wiley +1 more source
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source
Adipocyte‐derived palmitic acid induces ZDHHC15‐mediated PPARγ S‐palmitoylation at Cys159, triggering its proteasomal degradation and promoting breast cancer malignancy with rosiglitazone resistance. Inhibition of PPARγ S‐palmitoylation by 2‐bromopalmitate suppresses breast cancer progression and synergistically enhances rosiglitazone efficacy ...
Geon Ho Moon +6 more
wiley +1 more source

